KR101725696B1 - 신규한 이환형 피리딘온 - Google Patents

신규한 이환형 피리딘온 Download PDF

Info

Publication number
KR101725696B1
KR101725696B1 KR1020157006971A KR20157006971A KR101725696B1 KR 101725696 B1 KR101725696 B1 KR 101725696B1 KR 1020157006971 A KR1020157006971 A KR 1020157006971A KR 20157006971 A KR20157006971 A KR 20157006971A KR 101725696 B1 KR101725696 B1 KR 101725696B1
Authority
KR
South Korea
Prior art keywords
methyl
mmol
alkyl
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157006971A
Other languages
English (en)
Korean (ko)
Other versions
KR20150044948A (ko
Inventor
엔데 크리스토퍼 윌리엄 암
마이클 에릭 그린
더글라스 스콧 존슨
그레고리 웨인 카우프맨
크리스토퍼 존 오도넬
난디니 카터바이 파텔
마틴 영진 피터슨
안토니아 프리데리케 스테판
코리 마이클 스티프
카크라파니 서브라만얌
투안 퐁 트란
패트릭 로버트 버호에스트
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20150044948A publication Critical patent/KR20150044948A/ko
Application granted granted Critical
Publication of KR101725696B1 publication Critical patent/KR101725696B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020157006971A 2012-09-21 2013-09-06 신규한 이환형 피리딘온 Expired - Fee Related KR101725696B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703969P 2012-09-21 2012-09-21
US61/703,969 2012-09-21
PCT/IB2013/058347 WO2014045156A1 (en) 2012-09-21 2013-09-06 Novel bicyclic pyridinones

Publications (2)

Publication Number Publication Date
KR20150044948A KR20150044948A (ko) 2015-04-27
KR101725696B1 true KR101725696B1 (ko) 2017-04-10

Family

ID=49585452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157006971A Expired - Fee Related KR101725696B1 (ko) 2012-09-21 2013-09-06 신규한 이환형 피리딘온

Country Status (46)

Country Link
US (3) US8916564B2 (enExample)
EP (1) EP2897956B1 (enExample)
JP (1) JP5844018B2 (enExample)
KR (1) KR101725696B1 (enExample)
CN (1) CN104662021B (enExample)
AP (1) AP2015008277A0 (enExample)
AR (1) AR092628A1 (enExample)
AU (1) AU2013319845B2 (enExample)
BR (1) BR112015006436A2 (enExample)
CA (1) CA2882386C (enExample)
CL (1) CL2015000717A1 (enExample)
CR (1) CR20150053A (enExample)
CU (1) CU20150021A7 (enExample)
CY (1) CY1118662T1 (enExample)
DK (1) DK2897956T3 (enExample)
DO (1) DOP2015000069A (enExample)
EA (1) EA026668B1 (enExample)
EC (1) ECSP15015594A (enExample)
ES (1) ES2609987T3 (enExample)
GE (1) GEP201706659B (enExample)
GT (1) GT201500069A (enExample)
HR (1) HRP20161558T1 (enExample)
HU (1) HUE031248T2 (enExample)
IL (1) IL237163A (enExample)
IN (1) IN2015DN01119A (enExample)
LT (1) LT2897956T (enExample)
MA (1) MA37886B1 (enExample)
MD (1) MD4583B1 (enExample)
ME (1) ME02571B (enExample)
MX (1) MX360599B (enExample)
MY (1) MY181891A (enExample)
NI (1) NI201500038A (enExample)
NZ (1) NZ704863A (enExample)
PE (1) PE20150686A1 (enExample)
PH (1) PH12015500376B1 (enExample)
PL (1) PL2897956T3 (enExample)
PT (1) PT2897956T (enExample)
RS (1) RS55426B1 (enExample)
SG (1) SG11201501074WA (enExample)
SI (1) SI2897956T1 (enExample)
TN (1) TN2015000084A1 (enExample)
TW (1) TWI500616B (enExample)
UA (1) UA110688C2 (enExample)
UY (1) UY35039A (enExample)
WO (1) WO2014045156A1 (enExample)
ZA (1) ZA201501195B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
JP6425717B2 (ja) * 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3126361B1 (en) * 2014-04-01 2019-11-06 Pfizer Inc Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
JP6628805B2 (ja) * 2015-02-03 2020-01-15 ファイザー・インク 新規シクロプロパベンゾフラニルピリドピラジンジオン
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
CN109311876B (zh) 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
CN113402490B (zh) * 2021-03-29 2023-01-03 白银京宇新药业有限公司 一种1，2，6，7-四氢-8H-茚并[5，4-b]呋喃-8-酮的制备方法
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
CN114034792B (zh) * 2021-11-09 2024-06-25 山东新华制药股份有限公司 检测氯酮含量的液相色谱分析方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2013171712A1 (en) 2012-05-16 2013-11-21 Janssen Pharmaceuticals, Inc. Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419788A (en) 1972-08-02 1975-12-31 Pfizer Herbicidal method using 2-trifuluromethyl-4-quinolinols
WO1992000075A1 (en) 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
ATE161530T1 (de) 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
DE69628484T2 (de) 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CN1177616C (zh) 1997-04-09 2004-12-01 曼德塞特生物制药公司 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
WO1999044955A1 (en) 1998-03-03 1999-09-10 Ppg Industries Ohio, Inc. Impregnated glass fiber strands and products including the same
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
EP1145714A4 (en) 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd DRUGS
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
EP1551809A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20070155731A1 (en) 2004-01-28 2007-07-05 Gabor Butora Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
WO2005080361A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
JP2007528394A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
EP1730119B1 (en) 2004-03-23 2008-06-25 Pfizer Products Incorporated Imidazole compounds for the treatment of neurodegenerative disorders
PL1742642T3 (pl) 2004-04-14 2009-06-30 Gilead Sciences Inc Analogi fosfonianowe związków inhibitorów integrazy HIV
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
EP1881985B1 (en) 2005-05-12 2010-12-29 Pfizer, Inc. Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US20070060534A1 (en) 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007061923A2 (en) 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
EP1957465A4 (en) 2005-11-18 2009-04-08 Glaxo Group Ltd NEW INTERMEDIATE PRODUCTS AND THEIR USE
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
BRPI0618814A2 (pt) 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
EP1976843B1 (en) 2006-01-20 2013-09-04 Merck Sharp & Dohme Corp. Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
CN101454320B (zh) 2006-04-21 2012-12-19 辉瑞产品公司 吡啶并[3，4-b]吡嗪酮
WO2007136572A2 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
NZ572367A (en) 2006-05-16 2011-09-30 Gilead Sciences Inc Fused cyclic compounds as integrase inhibitors
WO2007135969A1 (ja) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. ウレア系－シンナミド誘導体
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
DE602008004769D1 (en) 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
AR066151A1 (es) 2007-06-01 2009-07-29 Schering Corp Moduladores de gama secretasa
EP2152695A2 (en) 2007-06-01 2010-02-17 Schering Corporation Gamma secretase modulators
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
WO2009005729A1 (en) 2007-06-29 2009-01-08 Schering Corporation Gamma secretase modulators
PE20090957A1 (es) 2007-08-06 2009-07-13 Schering Corp Moduladores de gamma secretasa
CA2694401C (en) 2007-08-31 2012-12-04 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
MX2010003397A (es) 2007-09-28 2010-04-09 Schering Corp Moduladores de la gamma secretasa.
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
US20100298359A1 (en) 2007-12-06 2010-11-25 Xianhai Huang Gamma secretase modulators
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CA2708151A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2009075874A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
JP2011513323A (ja) 2008-02-29 2011-04-28 シェーリング コーポレイション アルツハイマー病の治療のためのγ−セクレターゼモジュレーター
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
JP2011520809A (ja) 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
WO2010019393A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
JP2012501336A (ja) 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
WO2010054064A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
WO2010054067A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
EP2378879A4 (en) 2008-12-16 2012-06-06 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2379075A4 (en) 2008-12-16 2012-05-30 Merck Sharp & Dohme TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
EP2379566A2 (en) 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
KR20110118626A (ko) 2009-02-26 2011-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 테트라하이드로트리아졸로피리딘 유도체의 염과 이의 결정
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012121809A (ja) 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
CA2751534A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
AU2010279377B2 (en) 2009-08-07 2014-07-03 Dow Agrosciences Llc Pesticidal compositions
EP2491026A1 (en) * 2009-10-20 2012-08-29 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
NZ600954A (en) * 2009-12-22 2013-11-29 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
CN111772834B (zh) 2014-03-21 2022-07-15 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
EP3126361B1 (en) 2014-04-01 2019-11-06 Pfizer Inc Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2013171712A1 (en) 2012-05-16 2013-11-21 Janssen Pharmaceuticals, Inc. Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease

Also Published As

Publication number Publication date
DOP2015000069A (es) 2015-05-15
AU2013319845A1 (en) 2015-02-26
MA37886A1 (fr) 2016-02-29
CR20150053A (es) 2015-03-25
IN2015DN01119A (enExample) 2015-06-26
PH12015500376A1 (en) 2015-04-20
PL2897956T3 (pl) 2017-05-31
AP2015008277A0 (en) 2015-02-28
MA37886B1 (fr) 2016-09-30
HRP20161558T1 (hr) 2016-12-30
CA2882386A1 (en) 2014-03-27
EP2897956B1 (en) 2016-11-09
US20140088111A1 (en) 2014-03-27
CA2882386C (en) 2017-11-28
AU2013319845B2 (en) 2017-09-14
EP2897956A1 (en) 2015-07-29
EA026668B1 (ru) 2017-05-31
PE20150686A1 (es) 2015-05-23
LT2897956T (lt) 2017-01-10
US9751877B2 (en) 2017-09-05
CN104662021A (zh) 2015-05-27
NZ704863A (en) 2017-03-31
GT201500069A (es) 2016-03-01
KR20150044948A (ko) 2015-04-27
NI201500038A (es) 2015-06-05
ECSP15015594A (es) 2017-08-31
UY35039A (es) 2014-04-30
JP2015529238A (ja) 2015-10-05
ME02571B (me) 2017-06-20
TW201425311A (zh) 2014-07-01
MX360599B (es) 2018-11-08
US20160024088A1 (en) 2016-01-28
JP5844018B2 (ja) 2016-01-13
CN104662021B (zh) 2016-08-24
US20150072990A1 (en) 2015-03-12
AR092628A1 (es) 2015-04-29
US9193726B2 (en) 2015-11-24
GEP201706659B (en) 2017-04-25
EA201590319A1 (ru) 2015-09-30
RS55426B1 (sr) 2017-04-28
ZA201501195B (en) 2016-01-27
IL237163A0 (en) 2015-04-30
MD20150023A2 (ro) 2015-07-31
MX2015003637A (es) 2015-06-05
PT2897956T (pt) 2017-01-13
HUE031248T2 (en) 2017-06-28
US8916564B2 (en) 2014-12-23
DK2897956T3 (en) 2017-01-16
HK1206013A1 (zh) 2015-12-31
SI2897956T1 (sl) 2017-02-28
CY1118662T1 (el) 2017-07-12
CU20150021A7 (es) 2015-08-27
UA110688C2 (uk) 2016-01-25
BR112015006436A2 (pt) 2017-07-04
TN2015000084A1 (fr) 2016-06-29
WO2014045156A1 (en) 2014-03-27
PH12015500376B1 (en) 2015-04-20
MD4583B1 (ro) 2018-07-31
CL2015000717A1 (es) 2015-06-19
MY181891A (en) 2021-01-12
IL237163A (en) 2016-12-29
SG11201501074WA (en) 2015-05-28
ES2609987T3 (es) 2017-04-25
TWI500616B (zh) 2015-09-21

Similar Documents

Publication Publication Date Title
KR101725696B1 (ko) 신규한 이환형 피리딘온
AU2015242330B2 (en) Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
TW201300384A (zh) 新穎的雙環吡啶酮類
EP3052495B1 (en) Novel bicyclic pyridinones as gamma-secretase modulators
US9765073B2 (en) Cyclopropabenzofuranyl pyridopyrazinediones
US20160229847A1 (en) Novel bicyclic pyridinones as gamma-secretase modulators
HK1206013B (en) Novel bicyclic pyridinones
OA18058A (en) Chromene and 1,1 A,2,7B-tetrahydrocyclopropa[C]chromene pyridopyrazinediones as gamma-secretase modulators.
OA18546A (en) Novel cyclopropabenzofuranyl pyridopyrazinediones.

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220405

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220405

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000